Antiretroviral pharmacokinetic profile: a review of sex differences (Q36914113)

17 August 2017

1 reference

title

Antiretroviral pharmacokinetic profile: a review of sex differences (English)

1 reference

17 August 2017

main subject

anti-retroviral agent

0 references

1 reference

Ighovwerha Ofotokun

1

1 reference

17 August 2017

Susan K Chuck

series ordinal

2

1 reference

17 August 2017

Jane E Hitti

series ordinal

3

1 reference

17 August 2017

publication date

1 June 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

4

1 reference

17 August 2017

issue

2

1 reference

17 August 2017

page(s)

106-119

1 reference

Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

Severe adverse life events and depressive symptoms among women with, or at risk for, HIV infection in four cities in the United States of America

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

Sex differences in HAART-associated dyslipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

Sex differences in nevirapine rash

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

Sex differences in nevirapine rash

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

Intracellular carbovir triphosphate levels in patients taking abacavir once a day.

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

Adverse events from drug therapy for human immunodeficiency virus disease

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

Sex differences in nevirapine disposition in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

Population pharmacokinetic meta-analysis with efavirenz

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals.

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

Enhanced saquinavir exposure in human immunodeficiency virus type 1-infected patients with diarrhea and/or wasting syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men?

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients

1 reference

https://api.crossref.org/works/10.1016%2FS1550-8579%2807%2980025-8

7 January 2021

10.1016/S1550-8579(07)80025-8

Identifiers

DOI

1 reference

17 August 2017

1 reference